An overview of the status of acellular pertussis vaccines in practice

Drugs

Volumn 54, Issue 2, 1997, Pages 189-196

  Lopez, Anna Lena ^a   Blumberg, Dean A ^b  

^a UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; PERTUSSIS VACCINE;

BORDETELLA PERTUSSIS; DRUG EFFICACY; IMMUNOGENICITY; MORBIDITY; MORTALITY; PERTUSSIS; REVIEW; SIDE EFFECT; VACCINATION;

BORDETELLA PERTUSSIS;

EID: 0030810892     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754020-00001     Document Type: Review

References (45)

1. Cherry JD. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States. Curr Probl Pediatr 1984; 14: 1-78
2. Strebel P, Guris D, Tachdjian R, et al. Epidemiology of pertussis and the importance of laboratory diagnosis [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3-5: Washington, DC
3. Expanded Programme on Immunization. Global programme for vaccines and immunization: immunization policy. 1995: WHO Document WHO/EPI/GEN/95.3
4. Farizo KM, Cochi SL, Zell ER. et al. Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis 1992; 14: 708-19
5. Mink CM, Cherry JD, Christenson P. et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992; 14: 464-71
6. Rosenthal S, Strebel P, Cassiday P, et al. Pertussis infection among adults during the 1993 outbreak in Chicago. J Infect Dis 1995; 171: 1650-2
7. Wright SW, Edwards KM, Decker MD. et al. Pertussis infection in adults with persistent cough. JAMA 1995; 273: 1044-6
8. Deen JL, Mink CM, Cherry JD, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis 1995; 21: 1211-9
9. Mooi FR. Virulence factors of Bordetella pertussis. Antonie van Leeuwenhoek 1988; 54: 465-74
10. Tuonamen E, Weiss A. Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory epithelial cells. J Infect Dis 1985; 152: 118-25
11. Mortimer Jr EA. Pertussis vaccine. In: Plotkin SA. Mortimer Jr EA, editors. Vaccines. 2nd ed. Philadelphia: Saunders. 1994: 91-135
12. Tuomanen E, Weiss A, Rich R, et al. Filamentous hemagglutinin and pertussis toxin promote adherence of Bordetella pertussis to cilia. Dev Biol Stand 1985; 61: 197-204
13. Winsnes R. Serological responses to pertussis. In: Wardlaw AC. Parton RD. editors. Pathogenesis and immunity in pertussis. New York: John Wiley and Sons. 1988; 283-307
14. Cody CF, Baraff LJ, Cherry JD. et al. Nature and rates of adverse reactions associated with DTP and DT immunization in infants and children. Pediatrics 1981; 68: 650-60
15. Baraff LJ. Manclark CR. Cherry JD, et al. Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr Infect Dis J 1989; 8: 502-7
16. Blumberg DA, Lewis K, Mink CM. et al. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying. Pediatrics 1993; 91: 1158-65
17. American Academy of Pediatrics. Pertussis. In: Peter G. editor. 1994 Red Book: Report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village (IL): American Academy of Pediatrics. 1994: 355-67
18. Cherry JD. Acellular pertussis vaccines - a solution to the pertussis problem. J Infect Dis 1993; 168: 21-4
19. Kimura M, Kuno-Saki H, Developments in pertussis immunisation in Japan. Lancet 1990; 2: 30-2
20. Robinson A. Funnell SGP. Potency testing of acellular pertussis vaccines. Vaccine 1992; 10: 139-41
21. Shahin RD, Mink C, Wiedermann BL, et al. Laboratory correlates of protection and protective immunity to Bordetella pertussis. In: Ciardi JE. Mcghee JR, Keith J. editors. Genetically engineered vaccines: prospects for oral disease prevention. New York (NY): Plenum Publishers. 1992: 287-92
22. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96 Suppl.: 548-57
23. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 96 Suppl.: 557-66
24. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protective efficacy and adverse events [published erratum appears in Lancet 1988; I: 1238]. Lancet 1988; I: 955-60
25. Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N Engl J Med 1996; 334: 391-2
26. Gustafsson L. Hollander HO, Olin P, et al. A controlled trial of a two-component acellular and a five-componenl acellular and a whole-cell pertussis vaccine. N Engl J Med 1996; 334: 349-55
27. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole cell vaccine against pertussis. N Engl J Med 1996; 334: 341-8
28. Simondon F, Senegal pertussis trial [abstract]. National Institules of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3-5; Washington. DC
29. Plotkin S, Cadoz M. An interpretation of the acellular vaccine trials [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3-5: Washington. DC
30. Trollfors B, Taranger J, Lagergard T, et al. A placebo controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995; 333: 1045-50
31. Heininger U. Erlangen pertussis trial [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3-5; Washington. DC
32. Liese JG, Harzer E, Meschievitz CK, et al. Efficacy of BIKEN acellular pertussis vaccine combined with diphtheria-tetanus toxoids (Tripedia) in infants [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3-5: Washington. DC
33. Schmitt HJ, Zepp F, APV-050 Study Group. Immunogenicity, reactogenicity and protective efficacy of a three-component acellular pertussis (DTaP) vaccine in infants [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3-5: Washington, DC
34. Greco D, Salmaso S, Trial Working Group. The Italian trial on pertussis vaccine [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3-5; Washington. DC
35. WHO Meeting on Case Definition of Pertussis: 1991 Jan 10-11: Geneva. Geneva: World Health Organisation, 1991: 4-5 (issue no. MIN/EPI/PERT/91.1)
36. Centers for Disease Control. Food and Drug Administration approval of a second acellular pertussis vaccine for use among infants and young children. MMWR 1997; 46: 110-1
37. Centers for Disease Control. Food and Drug Administration approval of an acellular pertussis vaccine for the initial four doses of the diphtheria, tetanus and pertussis vaccination series. MMWR 1996; 45: 676-7
38. Cattaneo LA, Reed GW, Haase DH. et al. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years. J Infect Dis 1996; 173: 1256-9
39. Linneman CC, Ramundo N, Perlstein PH, et al. Use of pertussis vaccine in an epidemic involving hospital staff. Lancet 1975; 2: 540-3
40. Edwards KM, Decker MD, Graham BS, et al. Adult immunization with acellular pertussis vaccine. JAMA 1993; 269: 53-6
41. Greenberg DP, Wong VK, Partridge S, et al. Immunogenicity of a booster dose of Hib conjugate vaccine in children with impaired immune responses following primary vaccination with DTaP-Hep B-PRP-T vaccine [abstract no. G6q]. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996: 154
42. Meschievitz CK. Acellular DTP development at Pasteur Mérieux-Connaught [abstract]. National Institutes of Health Pertussis Conference: acellular pertussis vaccine trials. Results and impact on US public health: 1996 Jun 3-5; Washington, DC
43. Centers for Disease Control. FDA approval of a Haemophilus b conjugate vaccine combined by reconstitution with an acellular pertussis vaccine. MMWR 1996; 45: 993-5
44. Greenberg DP, Wong VK, Partridge S, et al. Evaluation of a new combination vaccine that incorporates diphtheria-tetanus-acellular pertussis (DTaP), hepatitis B (HB), and Haemophilus influenzae type b (Hib) conjugate (PRP-T) vaccines [abstract no. G70]. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995: 170
45. Pichichero M, Passador S. Response to an Haemophilus influenzae B (HIB) Conjugate vaccine booster following low antibody responses to simultaneous DTaP-HIB-hepatitis B combination vaccine in infants [abstract no. 1076]. Presented at the Pediatric Academic Societies Annual Meeting: 1996 May 6-10: Washington. DC